Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcri...
Prif Awduron: | , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Journal article |
Cyhoeddwyd: |
Springer Nature
2018
|